Citius Pharmaceuticals Inc CTXR

NAS: CTXR | ISIN: US17322U2078   31/05/2024
0,698 USD (+6,39%)
(+6,39%)   31/05/2024

29 mei 2024 · Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution · Persbericht

21 mei 2024 · Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution · Persbericht

14 mei 2024 · Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update · Persbericht

10 mei 2024 · Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences · Persbericht

30 april 2024 · Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering · Persbericht

26 april 2024 · Citius Pharmaceuticals Announces $15 Million Registered Direct Offering · Persbericht

11 april 2024 · Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma · Persbericht

4 april 2024 · Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference · Persbericht

18 maart 2024 · Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma · Persbericht

7 maart 2024 · Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program · Persbericht

26 februari 2024 · Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration · Persbericht

23 februari 2024 · Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences · Persbericht

14 februari 2024 · Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update · Persbericht

14 februari 2024 · Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma · Persbericht

23 januari 2024 · Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors · Persbericht

2 januari 2024 · Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters · Persbericht

2 januari 2024 · Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update · Persbericht

9 november 2023 · Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 · Persbericht

31 oktober 2023 · Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor · Persbericht

24 oktober 2023 · Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. · Persbericht

Mijn selecties